NCT00515450View on ClinicalTrials.gov

Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis

PHASE3CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

June 30, 2010

Conditions
Generalized Myasthenia Gravis
Interventions
BIOLOGICAL

GB-0998 (Intravenous immunoglobulin)

PROCEDURE

Plasmapheresis

Trial Locations (1)

852-8501

Nagasaki University, Nagasaki

Sponsors
All Listed Sponsors
lead

Benesis Corporation

INDUSTRY

NCT00515450 - Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis | Biotech Hunter | Biotech Hunter